The original content of Democracy Now! Headlines appears under the Creative
Commons BY-NC-ND 3.0 License (United States). For more, including their other
shows and media, visit www.democracynow.org.
July 18, 2023

New Experimental Drug Shows Promise at Slowing Progression of Alzheimer's Disease
---------------------------------------------------------------------------------

In medical news, an experimental new drug called donanemab has slowed
the progression of Alzheimer's disease in patients by about 35%, when
used in the early stages of the disease. That makes the drug at least as
effective as Leqembi, another monoclonal antibody treatment against
Alzheimer's that won FDA approval earlier this month. Drugmaker Eli
Lilly hasn't said how much donanemab would cost if it wins regulatory
approval, but a year's treatment of Leqembi has been priced at more than
$26,000 in the U.S.


.